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Abstract
Background: Streptococcus pneumoniae is a major cause of human disease, especially in pre-school
children and elderly people, as well as in special risk groups such as asplenic, antibody deficient
patients, or presenting disruption of natural barriers. The occurrence of pneumococcal disease has
increased with the onset of the HIV epidemic and the emergence of drug-resistance.
Case presentation: We report the case of an HIV-1-infected patient who experienced three
episodes of recurrent pneumococcal meningitis over a 4-year period, despite chemoprophylaxis
and capsular vaccination.
Conclusions: Efficacy of anti-pneumococcal chemoprophylaxis and vaccination in HIV-infected
patients are discussed in the light of this particular case.
Background
Streptococcus pneumoniae is a Gram-positive, encapsulated
bacterium that is a major human pathogen, predomi-
nantly in young children and elderly people, as well as in
patients presenting with asplenia, sickle cell disease, and
inherited or acquired immunodeficiencies [1]. In industri-
alized countries, where vaccination against Haemophilus
influenzae type b is widespread, S. pneumoniae has become
a major cause of bacterial meningitis, together with Neis-
seria meningitidis, and bacterial meningitis is now a disease
predominantly of adults rather than of infants and chil-
dren [2,3]. In the developing world, bacterial meningitis
remains a major problem, with increased incidence and
mortality compared to more developed countries [4,5].
With the onset of the HIV pandemic and the worldwide
emergence of drug-resistant pneumococci, the incidence
of invasive pneumococcal infection has increased in
adults as well as children [6–9], and pneumococcal vac-
cine was recommended in the USPHS/IDSA guidelines for
the management of HIV-infected patients. We report the
case of an HIV-infected patient who experienced three epi-
sodes of recurrent pneumococcal meningitis over a 4-year
period, despite anti-pneumococcal vaccination and
chemoprophylaxis.
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Case presentation
A 29 year-old patient was found to be HIV-1-infected
through investigations for an idiopathic thrombocyto-
penic purpura in 1989. After unsuccessful medical treat-
ments, splenectomy was performed and anti-
pneumococcal chemoprophylaxis (phenoxymethylpeni-
cillin, 2 MU/day) was carried out until 1996. Meanwhile,
a series of HIV-related infections occurred: Pneumocystis
carinii pneumonia in 1993, herpetic esophagitis, herpetic
anorectal lesions and cutaneous Kaposi's sarcoma in
1995, CMV retinitis, Mycobacterium avium complex infec-
tion, facial molluscum contagiosum and catheter-borne sep-
ticaemias due to Pseudomonas aeruginosa and
Staphylococcus epidermidis. Since the rifabutin anti-M.
avium treatment would also be efficient against pneumo-
coccal infections, the specific anti-pneumococcal prophy-
laxis was stopped in 1996. After several lines of
mononucleoside therapy, a combination of stavudine,
lamivudine and nelfinavir was started in 1997, the biolog-
ical efficacy of which allowed the interruption of the pro-
phylactic ganciclovir treatment in December 1998, and
that of cotrimoxazole in March 1999.
The first episode of pneumococcal meningitis (Table 1)
occurred in 1998, and was successfully treated with the
association of cefotaxime (12 g/day, 17 days) and vanco-
mycin (3 g/day, 12 days). The pneumococcal strain iso-
lated from the CSF belonged to serotype 23F and
exhibited a decreased susceptibility to penicillin (Minimal
Inhibitory Concentration (MIC) = 1.0 µg/ml), and was
resistant to erythromycin and clindamycin. A bilateral
maxillary sinusitis diagnosed a few weeks before was con-
sidered as the likely portal of entry. No specific anti-pneu-
mococcal prophylaxis, which had been stopped two years
earlier, was prescribed at that time.
Two and a half years later, in 2000, a second meningitic
episode occurred. Blood and CSF cultures yielded the
presence of a serotype 23F pneumococcal strain, with
identical antibiotic susceptibility to that of the first epi-
sode (Table 1). The patient was successfully treated using
ceftriaxone (2 g/day) and vancomycin (2 g/day).
Although no pneumococcal carriage or distant focal infec-
tion could be detected, chemoprophylaxis was reintro-
duced (phenoxymethylpenicillin, 3 MU/day).
Furthermore, the patient received the 23-valent capsular
pneumococcal vaccine (Pasteur Vaccins, Lyon, France).
Six months later, the patient was admitted in intensive
care unit for meningitis. Culture of the CSF showed the
presence of a serotype 23F S. pneumoniae that was resistant
to penicillin (MIC = 2 µg/ml), but susceptible to ceftriax-
one (MIC 0,75 µg/l). Successful treatment was obtained
using ceftriaxone (6 g/day) and vancomycin (2 g/day) for
15 days. Radiology imaging of the mastoids and of the
skull did not show any abnormal sign, and neither pneu-
mococcal carriage nor concomitant infection could be
detected. Radio-isotopic imaging disclosed no breach of
the meninges. After antibiotic treatment was successfully
completed, an anti-pneumococcal chemoprophylaxy was
decided (amoxicillin 2 g/day), as well as conjugate anti-
pneumococcal vaccination (Wyeth-Ayerst Laboratories,
Philadelphia, PA, USA). The patient was monitored and
has done well more than two years after this third episode.
Analysis by pulsed-field gel electrophoresis (PFGE) of
SmaI-restricted genomic DNA of the first and the third iso-
lates revealed that the restriction profiles were not distin-
guishable from each other, and were different from those
obtained with unrelated pneumococcal strains from our
collection (data not shown). Unfortunately, it was not
possible to include the isolate responsible for the second
episode in the PFGE study.
Together with the fact that the three pneumococcal iso-
lates were of serotype 23F, PFGE analysis strongly suggests
that both isolates belong to the same clone. Moreover, the
three strains exhibited the same antibiotic resistance pat-
terns, apart from an increased MIC to penicillin in the
third isolate (Table 1). Therefore, it is very likely that the
Table 1: Biological characteristics of the three meningitic episodes
Episode 1 (March 1998) Episode 2 (May 2000) Episode 3 (January 2001)
CSF characteristics Glucose: not detectable Glucose: 1 mM Glucose: 0.4 mM
Proteins: 3.2 g/l Proteins: 2.9 g/l Proteins: 2.2 g/l
Leucocytes: 670/mm3 (96%PMN) Leucocytes: 2100/mm3 (51%PMN) Leucocytes: 8100/mm3 (85%PMN)
Positive culture with S. pneumoniae 
23F
Positive culture with S. pneumoniae 
23F
Positive culture with S. pneumoniae 
23F
Beta-lactam penicillin G: 1.0 penicillin G: 1.0 penicillin G: 2.0
susceptibility amoxicillin: 0.75 amoxicillin: 0.75 amoxicillin: 0.75
MICs (µg/ml) ceftriaxone: 0.75 ceftriaxone: 0.75 ceftriaxone: 0.75
CD4 (1O6 cells/l – %) 325 – 13 1103 – 21 1185 – 20
Viral load (copies/ml – Log10) 280 – 2.5 1300 – 3.1 2000 – 3.3Annals of Clinical Microbiology and Antimicrobials 2003, 2 http://www.ann-clinmicrob.com/content/2/1/9
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three meningitic episodes were caused by the same pneu-
mococcal strain, and that successive curative and prophy-
lactic antibiotic treatments led to the selection of
derivatives with decreased susceptibility to penicillin G.
Conclusions
In this case, the occurrence of three episodes of pneumo-
coccal meningitis over a 4-year period highlights the con-
troversial efficacy of vaccination and antibiotic
prophylaxis in HIV-1-infected patients. Recurrent menin-
gitis is a rare disease that is often associated with cranial
injuries, and S. pneumoniae is responsible for more than
half of the recurrent purulent bacterial meningoencepha-
litis [10]. The first episode was probably due to the bilat-
eral maxillary sinusitis, as was already reported [11].
Furthermore, the infection with HIV-1 and the splenec-
tomy were also shown to be additional risk factors [12–
14,7]. However, at the time of anti-pneumococcal vacci-
nation and before the third episode occurred, the patient
had CD4+ cell count greater than 500 cells/µl, which was
reported to decrease the risk of pneumococcal disease [7].
The patient was not receiving anti-pneumococcal chemo-
prophylaxis when the first and second episodes occurred.
However, when the third episode occurred, the patient
had been subjected to 23-valent capsular vaccination and
was receiving chemoprophylaxis, as well as a biologically
efficient antiretroviral treatment. Although the patient's
compliance to the treatment could not be thoroughly
assessed, this case highlights the uncertain efficacy of che-
moprophylaxis [15], and differs from other previously
reported cases in immunocompetent patients, where cap-
sular vaccination and ampicillin prophylaxis were shown
to reduce the recurrence rate of pneumococcal meningitis
[16].
This observation also highlights the controversial effect of
pneumococcal vaccination in HIV-infected patients. Some
authors consider that potential benefit of capsular vacci-
nation is greater than risk [17,18,7], and anti-pneumococ-
cal capsular vaccination figures among the USPHS/IDSA
recommended guidelines for the management of HIV-
infected patients. However, other works have shown that
23-valent pneumococcal polysaccharide vaccination may
be poorly effective in HIV-1-infected adults, especially
among African-American persons and people in Uganda
[18–22], and other reports suggested that it might be
more cost-effective to concentrate efforts on anti-retroviral
therapy [23]. Efficacy of vaccination in HIV-1-infected
patients receiving HAART (Highly Active Anti-Retroviral
Therapy) is poorly documented, but recent reports
showed that pneumococcal capsular polysaccharide vacci-
nation in such patients induces a qualitative change in
antibody response compared with non-HAART-treated
patients [24]. This involves an increased VH3-positive
antibody response, which had been shown to be present
in vaccine response of HIV-uninfected patients. Taken
together, recommendations for use of non-conjugated
pneumococcal polysaccharide vaccines in HIV-infected
people should be re-assessed, particularly in the identifi-
cation of sub-groups most likely to benefit from the vac-
cine [25].
The patient experienced no other recurrence of pneumo-
coccal infection more than two years after vaccination
with the conjugated heptavalent capsular vaccine. As well
as the non-conjugated 23-valent capsular vaccine, this
new generation of vaccine also covers serotype 23F, and
was described to possibly interrupt the transmission of
antibiotic-resistant S. pneumoniae among children [26].
Administration of conjugated vaccines in HIV-infected
patients was reported to be safe, and to have no peculiar
effect on viral load [27,28]. Furthermore, vaccination reg-
imens that include pneumococcal conjugate vaccines lead
to higher antibody concentration and greater functional
antibody activity [27]. A trial of a 9-valent pneumococcal
conjugate vaccine recently showed a potential efficacy in
HIV-infected children, and suggest that such an approach
should be investigated in HIV-infected adults [29]. How-
ever, further studies are needed to evaluate if conjugated
capsular vaccines should be introduced in the systematic
care of HIV-1-infected patients.
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